文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

冠状动脉内和逆行冠状静脉心肌内注射脂肪来源干细胞可导致猪梗塞后的短暂心肌滞留,主要向肺部重新分布。

Intracoronary and retrograde coronary venous myocardial delivery of adipose-derived stem cells in swine infarction lead to transient myocardial trapping with predominant pulmonary redistribution.

机构信息

Krannert Institute of Cardiology, Indianapolis; Indiana Center for Vascular Biology and Medicine, Indianapolis; Indiana University School of Medicine, Indianapolis, Indianapolis; Korea University Anam Hospital, Seoul, Korea.

出版信息

Catheter Cardiovasc Interv. 2014 Jan 1;83(1):E17-25. doi: 10.1002/ccd.24659. Epub 2013 Oct 7.


DOI:10.1002/ccd.24659
PMID:22972685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4181717/
Abstract

OBJECTIVES: To examine the comparative fate of adipose-derived stem cells (ASCs) as well as their impact on coronary microcirculation following either retrograde coronary venous (RCV) or arterial delivery. BACKGROUND: Local delivery of ASCs to the heart has been proposed as a practical approach to limiting the extent of myocardial infarction. Mouse models of mesenchymal stem cell effects on the heart have also demonstrated significant benefits from systemic (intravenous) delivery, prompting a question about the advantage of local delivery. There has been no study addressing the extent of myocardial vs. systemic disposition of ASCs in large animal models following local delivery to the myocardium. METHODS: In an initial experiment, dose-dependent effects of ASC delivery on coronary circulation in normal swine were evaluated to establish a tolerable ASC dosing range for intracoronary (IC) delivery. In a set of subsequent experiments, an anterior acute myocardial infarction (AMI) was created by balloon occlusion of the proximal left anterior descending (LAD) artery, followed by either IC or RCV infusion of 10(7) (111)Indium-labeled autologous ASCs 6 days following AMI. Indices of microcirculatory resistance (IMR) and coronary flow reserve (CFR) were measured before sacrifices to collect tissues for analysis at 1 or 24 hr after cell delivery. RESULTS: IC delivery of porcine ASCs to normal myocardium was well tolerated up to a cumulative dose of 14 × 10(6) cells (approximately 0.5 × 10(6) cells/kg). There was evidence suggesting microcirculatory trapping of ASC: at unit doses of 50 × 10(6) ASCs, IMR and CFR were found to be persistently altered in the target LAD distribution at 7 days following delivery, whereas at 10 × 10(6) ASCs, only CFR was altered. In the context of recent MI, a significantly higher percentage of ASCs was retained at 1 hr with IC delivery compared with RCV delivery (57.2 ± 12.7% vs. 17.9 ± 1.6%, P = 0.037) but this initial difference was not apparent at 24 hr (22.6 ± 5.5% vs. 18.7 ± 8.6%; P = 0.722). In both approaches, most ASC redistributed to the pulmonary circulation by 24 hr postdelivery. There were no significant differences in CFR or IMR following ASC delivery to infarcted tissue by either route. CONCLUSIONS: Selective intravascular delivery of ASC by coronary arterial and venous routes leads to similarly limited myocardial cell retention with predominant redistribution of cells to the lungs. IC arterial delivery of ASC leads to only transiently greater myocardial retention, which is accompanied by obstruction of normal regions of coronary microcirculation at higher doses. The predominant intrapulmonary localization of cells following local delivery via both methods prompts the notion that systemic delivery of ASC might provide similarly beneficial outcomes while avoiding risks of inadvertent microcirculatory compromise.

摘要

目的:研究脂肪来源的干细胞(ASCs)在逆行冠状静脉(RCV)或动脉给药后的比较命运及其对冠状动脉微循环的影响。

背景:将 ASCs 局部递送至心脏已被提议作为限制心肌梗死程度的实用方法。间充质干细胞对心脏影响的小鼠模型也显示出全身(静脉内)给药的显著益处,这促使人们对局部给药的优势产生疑问。尚无研究探讨在大动物模型中,局部递送至心肌后,ASCs 在心肌与全身之间的分布程度。

方法:在初始实验中,评估了 ASC 给药剂量对正常猪冠状动脉循环的剂量依赖性影响,以确定可接受的冠状动脉内(IC)给药 ASC 剂量范围。在一系列后续实验中,通过气囊闭塞近端左前降支(LAD)动脉创建急性前壁心肌梗死(AMI),然后在 AMI 后 6 天通过 IC 或 RCV 输注 10(7)(111)Indium 标记的自体 ASCs。在牺牲前测量微血管阻力(IMR)和冠状动脉血流储备(CFR)指数,以收集细胞给药后 1 或 24 小时的组织进行分析。

结果:IC 递送至正常心肌的猪 ASC 可耐受高达 14×10(6)个细胞的累积剂量(约 0.5×10(6)个细胞/kg)。有证据表明 ASC 存在微循环捕获:在 50×10(6)个 ASC 的单位剂量下,在给药后 7 天,在目标 LAD 分布中发现 IMR 和 CFR 持续改变,而在 10×10(6)个 ASC 时,仅 CFR 改变。在最近的 MI 背景下,与 RCV 给药相比,IC 给药时在 1 小时时保留的 ASC 百分比显著更高(57.2±12.7%比 17.9±1.6%,P=0.037),但在 24 小时时这种初始差异并不明显(22.6±5.5%比 18.7±8.6%;P=0.722)。在两种方法中,在给药后 24 小时内,大多数 ASC 重新分布到肺循环。通过两种途径将 ASC 递送至梗死组织后,CFR 或 IMR 均无显著差异。

结论:通过冠状动静脉途径选择性的血管内递送 ASC 导致类似的有限心肌细胞保留,主要将细胞重新分布到肺部。IC 动脉内递送 ASC 仅导致短暂的心肌保留增加,同时在更高剂量时伴有正常冠状动脉微循环的阻塞。通过两种方法局部递送至心脏后,细胞主要在肺内定位,这提示全身递送 ASC 可能提供类似的有益结果,同时避免无意中损害微循环的风险。

相似文献

[1]
Intracoronary and retrograde coronary venous myocardial delivery of adipose-derived stem cells in swine infarction lead to transient myocardial trapping with predominant pulmonary redistribution.

Catheter Cardiovasc Interv. 2013-10-7

[2]
Intravenous xenogeneic transplantation of human adipose-derived stem cells improves left ventricular function and microvascular integrity in swine myocardial infarction model.

Catheter Cardiovasc Interv. 2015-8

[3]
Influence of Local Myocardial Damage on Index of Microcirculatory Resistance and Fractional Flow Reserve in Target and Nontarget Vascular Territories in a Porcine Microvascular Injury Model.

JACC Cardiovasc Interv. 2018-3-28

[4]
Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study.

Stem Cell Res Ther. 2017-3-9

[5]
Rat adipose tissue-derived stem cells transplantation attenuates cardiac dysfunction post infarction and biopolymers enhance cell retention.

PLoS One. 2010-8-10

[6]
Intracoronary Infusion of Thioflavin-S to Study Microvascular Obstruction in a Model of Myocardial Infarction.

Rev Esp Cardiol (Engl Ed). 2015-11

[7]
Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials.

Circulation. 2005-8-30

[8]
Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction.

J Am Heart Assoc. 2017-5-3

[9]
Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial.

Clin Res Cardiol. 2006-1

[10]
Intracoronary stem-cell injection after myocardial infarction: microcirculation sub-study.

Arq Bras Cardiol. 2011-10-7

引用本文的文献

[1]
Stem Cell Therapy for Myocardial Infarction Recovery: Advances, Challenges, and Future Directions.

Biomedicines. 2025-5-16

[2]
Stem Cell-Based Therapy and Cell-Free Therapy as an Alternative Approach for Cardiac Regeneration.

Stem Cells Int. 2023-11-2

[3]
ADSC-derived exosomes attenuate myocardial infarction injury by promoting miR-205-mediated cardiac angiogenesis.

Biol Direct. 2023-2-27

[4]
Therapeutic payload delivery to the myocardium: Evolving strategies and obstacles.

JTCVS Open. 2022-5-5

[5]
Lower retention after retrograde coronary venous infusion compared with intracoronary infusion of mesenchymal stromal cells in the infarcted porcine myocardium.

BMJ Open Sci. 2019-1-7

[6]
PPARβ/δ Is Required for Mesenchymal Stem Cell Cardioprotective Effects Independently of Their Anti-inflammatory Properties in Myocardial Ischemia-Reperfusion Injury.

Front Cardiovasc Med. 2021-9-20

[7]
Targeted delivery of therapeutic agents to the heart.

Nat Rev Cardiol. 2021-6

[8]
Cortical Bone Derived Stem Cells Modulate Cardiac Fibroblast Response via miR-18a in the Heart After Injury.

Front Cell Dev Biol. 2020-6-23

[9]
Unmodified autologous stem cells at point of care for chronic myocardial infarction.

World J Stem Cells. 2019-10-26

[10]
Plasticity of Adipose Tissue-Derived Stem Cells and Regulation of Angiogenesis.

Front Physiol. 2018-11-26

本文引用的文献

[1]
A long road for stem cells to cure sick hearts: update on recent clinical trials.

Korean Circ J. 2012-2-27

[2]
First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction.

J Am Coll Cardiol. 2012-1-31

[3]
Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina.

J Transl Med. 2011-10-26

[4]
Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6.

Stem Cell Res Ther. 2011-5-13

[5]
Adult stem cells in the treatment of acute myocardial infarction.

Catheter Cardiovasc Interv. 2011-1-1

[6]
Effects of adipose tissue-derived stem cell therapy after myocardial infarction: impact of the route of administration.

J Card Fail. 2010-2-9

[7]
Is stem cell-based therapy going on or out for cardiac disease?

Korean Circ J. 2009-3-25

[8]
Therapeutic potential of adipose-derived stem cells in vascular growth and tissue repair.

Curr Opin Organ Transplant. 2010-2

[9]
Adipose tissue-derived stem cells inhibit neointimal formation in a paracrine fashion in rat femoral artery.

Am J Physiol Heart Circ Physiol. 2009-11-25

[10]
Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts.

Am J Physiol Heart Circ Physiol. 2009-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索